JP2005527599A5 - - Google Patents

Download PDF

Info

Publication number
JP2005527599A5
JP2005527599A5 JP2004500866A JP2004500866A JP2005527599A5 JP 2005527599 A5 JP2005527599 A5 JP 2005527599A5 JP 2004500866 A JP2004500866 A JP 2004500866A JP 2004500866 A JP2004500866 A JP 2004500866A JP 2005527599 A5 JP2005527599 A5 JP 2005527599A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
administered
zonisamide
alkali metal
metal salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2004500866A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005527599A (ja
Filing date
Publication date
Priority claimed from US10/429,474 external-priority patent/US20040029941A1/en
Application filed filed Critical
Publication of JP2005527599A publication Critical patent/JP2005527599A/ja
Publication of JP2005527599A5 publication Critical patent/JP2005527599A5/ja
Withdrawn legal-status Critical Current

Links

JP2004500866A 2002-05-06 2003-05-05 肥満および摂食障害におけるゾニサミドの使用 Withdrawn JP2005527599A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37844602P 2002-05-06 2002-05-06
US10/429,474 US20040029941A1 (en) 2002-05-06 2003-05-02 Zonisamide use in obesity and eating disorders
PCT/US2003/014459 WO2003092682A1 (en) 2002-05-06 2003-05-05 Zonisamide use in obesity and eating disorders

Publications (2)

Publication Number Publication Date
JP2005527599A JP2005527599A (ja) 2005-09-15
JP2005527599A5 true JP2005527599A5 (enExample) 2006-09-14

Family

ID=29406837

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004500866A Withdrawn JP2005527599A (ja) 2002-05-06 2003-05-05 肥満および摂食障害におけるゾニサミドの使用

Country Status (5)

Country Link
US (2) US20040029941A1 (enExample)
EP (1) EP1503755A1 (enExample)
JP (1) JP2005527599A (enExample)
AU (1) AU2003228933A1 (enExample)
WO (1) WO2003092682A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2341259C2 (ru) * 2002-05-17 2008-12-20 Дюк Юниверсити Способ лечения ожирения
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
US20050059718A1 (en) * 2003-02-21 2005-03-17 Hayato Miyachi Methods of using zonisamide as an adjunctive therapy for partial seizures
PT2316456T (pt) 2003-04-29 2017-09-05 Orexigen Therapeutics Inc Composições para afetar a perda de peso compreendendo naltrexona e bupropion
US20050043773A1 (en) * 2003-08-21 2005-02-24 Ivan Lieberburg Methods of improving the safety of zonisamide therapy
US20050043704A1 (en) * 2003-08-21 2005-02-24 Eisai Co., Ltd Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050043705A1 (en) * 2003-08-21 2005-02-24 Eisai Co., Ltd. Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050154033A1 (en) * 2004-01-08 2005-07-14 Eisai Co., Ltd Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050154034A1 (en) * 2004-01-08 2005-07-14 Eisai Co., Ltd. Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050154032A1 (en) * 2004-01-08 2005-07-14 Eisai Co., Ltd Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050154037A1 (en) * 2004-01-09 2005-07-14 Eisai Co., Ltd. Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050154035A1 (en) * 2004-01-09 2005-07-14 Eisai Co., Ltd. Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050154036A1 (en) * 2004-01-09 2005-07-14 Eisai Co., Ltd. Methods of using zonisamide as an adjunctive therapy for partial seizures
US7713959B2 (en) 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
US20060160750A1 (en) * 2004-01-13 2006-07-20 Krishnan K R R Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
EP1734955A2 (en) * 2004-01-13 2006-12-27 Duke University Compositions of an anticonvulsant and an antipsychotic drug for affecting weigt loss
WO2005107806A1 (en) * 2004-04-21 2005-11-17 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
RU2006139930A (ru) * 2004-05-03 2008-06-10 Дюк Юниверсити (Сша/Сша) (Us) Составы для содействия снижению веса
US20050267221A1 (en) * 2004-05-14 2005-12-01 Research Development Foundation Use of curcumin and analogues thereof as inhibitors of ACC2
WO2006133045A1 (en) * 2005-06-03 2006-12-14 Elan Pharma International, Limited Nanoparticulate benidipine compositions
CN101370488B (zh) 2005-11-22 2012-07-18 奥雷西根治疗公司 增加胰岛素敏感性的组合物
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US20080110792A1 (en) * 2006-11-09 2008-05-15 Orexigen Therapeutics, Inc. Methods for administering weight loss medications
KR101971218B1 (ko) * 2006-11-09 2019-08-27 오렉시젠 세러퓨틱스 인크. 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
MX2010012909A (es) * 2008-05-30 2011-02-25 Orexigen Therapeutics Inc Metodos para tratamiento de condiciones de grasa visceral.
KR101841442B1 (ko) * 2010-01-11 2018-03-23 오렉시젠 세러퓨틱스 인크. 주우울증 환자들에 있어서 체중 감량 치료를 제공하는 방법
IL300868A (en) 2012-06-06 2023-04-01 Orexigen Therapeutics Inc Methods for treating overweight and obesity
CA2917702A1 (en) 2013-07-18 2015-01-22 Jazz Pharmaceuticals International Iii Limited Treatment for obesity
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
EP3452041A4 (en) 2016-03-07 2020-11-11 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Compositions and methods for administering ppar agonists, surfactant peptides and phospholipids
EP3638205A4 (en) 2017-06-14 2021-03-17 Semma Therapeutics, Inc. DEVICES AND METHODS FOR ADMINISTERING THERAPEUTICS
WO2019038584A1 (en) 2017-08-19 2019-02-28 Ftf Pharma Private Limited An oral pharmaceutical composition comprising zonisamide and process of preparation thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US25038A (en) * 1859-08-09 Egg-beater or churn
US33965A (en) * 1861-12-17 Improvement in rifle-sights
US4172896A (en) * 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US5719197A (en) * 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5853975A (en) * 1994-08-23 1998-12-29 Millennium Pharmaceuticals, Inc. Methods for identifying compositions for the treatment of body weight disorders, including obesity
US5576321A (en) * 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems
PT915697E (pt) * 1996-06-28 2003-02-28 Ortho Mcneil Pharm Inc Anticonvulsionantes derivados do sulfamato uteis no tratamento da obesidade
US6262049B1 (en) * 1997-10-28 2001-07-17 Schering Corporation Method of reducing nicotine and tobacco craving in mammals
ES2238999T3 (es) * 1999-02-24 2005-09-16 University Of Cincinnati Uso de derivados de sulfamato para tratar trastornos en el control de los impulsos.
JP2002541129A (ja) * 1999-04-01 2002-12-03 エスペリオン セラピューティクス インコーポレイテッド エーテル化合物、組成物、およびそれらの使用
US6403657B1 (en) * 1999-10-04 2002-06-11 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity
US6437147B1 (en) * 2000-03-17 2002-08-20 Novo Nordisk Imidazole compounds
US6555519B2 (en) * 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
US6191117B1 (en) * 2000-07-10 2001-02-20 Walter E. Kozachuk Methods of producing weight loss and treatment of obesity
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
RU2341259C2 (ru) * 2002-05-17 2008-12-20 Дюк Юниверсити Способ лечения ожирения
EP1734955A2 (en) * 2004-01-13 2006-12-27 Duke University Compositions of an anticonvulsant and an antipsychotic drug for affecting weigt loss

Similar Documents

Publication Publication Date Title
JP2005527599A5 (enExample)
JP2005537268A5 (enExample)
JP2006523216A5 (enExample)
JP2002522485A5 (enExample)
PT1173178E (pt) Composicao compreendendo apomorfina e sildenafil e utilizacao da mesma para o tratamento da disfuncao erectil
NZ527113A (en) Rapid-onset medicament for the treatment of sexual dysfunction
JP2004519469A5 (enExample)
JP2006503850A5 (enExample)
JP2005515966A5 (enExample)
JP2006515351A5 (enExample)
JP2023116697A5 (enExample)
JP2009506054A5 (enExample)
JP2001518509A5 (enExample)
WO2004045593A3 (en) Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
JP2009515901A5 (enExample)
JP2004537500A5 (enExample)
JP2002540148A5 (enExample)
CN110755432A (zh) 烟酰胺在制备治疗手足皮肤反应制剂中的应用
JP2008516909A5 (enExample)
JP2005513105A5 (enExample)
Smith et al. Evaluation of topotecan in patients with recurrent for metastatic squamous cell carcinoma of the head and neck: A phase II Southwest Oncology Group study
JPH0455172B2 (enExample)
JPWO2022234457A5 (enExample)
JPS62426A (ja) 新生物疾患の治療方法
Botea Analgesics